{"id":745040,"date":"2014-02-05T06:40:00","date_gmt":"2014-02-05T06:40:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/"},"modified":"2023-03-22T00:04:59","modified_gmt":"2023-03-22T04:04:59","slug":"merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/","title":{"rendered":"Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475"},"content":{"rendered":"<p class=\"bwalignc\">       Merck Also to Initiate Phase I \u201cSignal Finding\u201d Study with MK-3475        in 20 New Cancer Types     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today it has signed three separate clinical collaboration<br \/>\n      agreements, through subsidiaries, with Amgen Inc., Incyte Corporation<br \/>\n      and Pfizer Inc. to evaluate novel combination regimens with MK-3475,<br \/>\n      Merck\u2019s investigational anti-PD-1 immunotherapy. The financial terms of<br \/>\n      the agreements were not disclosed.\n    <\/p>\n<p>\n      \u201cMerck clinical scientists intend to explore the potential of our PD-1<br \/>\n      inhibitor across a wide range of cancers, both as monotherapy and in<br \/>\n      combination,\u201d said Dr. Roger M. Perlmutter, president, Merck Research<br \/>\n      Laboratories. \u201cThese new collaborations with Amgen, Incyte and Pfizer<br \/>\n      underscore our shared determination to evaluate treatment regimens with<br \/>\n      the potential to provide meaningful benefits to patients suffering from<br \/>\n      cancer.\u201d\n    <\/p>\n<p>\n      Planned investigations include:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Pfizer and Merck will evaluate in Phase I\/II clinical studies the<br \/>\n        safety and efficacy of MK-3475 in combination with Pfizer\u2019s small<br \/>\n        molecule kinase inhibitor axitinib (INLYTA\u00ae) in patients with renal<br \/>\n        cell carcinoma, and separately MK-3475 plus PF-05082566 (PF-2566), an<br \/>\n        investigational immuno-oncology agent that targets the human 4-1BB<br \/>\n        receptor, in multiple cancer types.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Incyte and Merck will collaborate on a randomized, double-blind<br \/>\n        placebo controlled Phase I\/II study to evaluate the safety and<br \/>\n        efficacy of a regimen combining MK-3475 with Incyte\u2019s investigational<br \/>\n        immunotherapy agent, INCB24360, an indoleamine 2, 3-dioxygenase (IDO)<br \/>\n        inhibitor, in patients with previously treated metastatic and<br \/>\n        recurrent NSCLC, among other advanced or metastatic cancers.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Amgen and Merck will evaluate MK-3475 in combination with Amgen\u2019s<br \/>\n        investigational oncolytic immunotherapy talimogene laherparepvec in a<br \/>\n        Phase I\/II study in patients with previously untreated advanced<br \/>\n        melanoma.\n      <\/li>\n<\/ul>\n<p>\n      Separately, Merck announced it will start a new Phase I \u201csignal finding\u201d<br \/>\n      study to evaluate the safety and efficacy of MK-3475 monotherapy in 20<br \/>\n      different PD-L1-positive solid tumor types that have not been studied<br \/>\n      previously (clinical trials identifier: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02054806%3Fterm%3DMK-3475%26rank%3D7&amp;esheet=50797474&amp;newsitemid=20140205005453&amp;lan=en-US&amp;anchor=NCT02054806&amp;index=1&amp;md5=590d3bba42533fec5ead584346b49db0\" rel=\"nofollow\">NCT02054806<\/a>).\n    <\/p>\n<p>\n      <b>About MK-3475<\/b>\n    <\/p>\n<p>\n      Many tumors are able to evade the immune system through a mechanism that<br \/>\n      exploits the PD-1 inhibitory checkpoint protein. MK-3475 is an<br \/>\n      investigational, highly selective anti-PD-1 immunotherapy designed to<br \/>\n      restore the natural ability of the immune system to recognize and target<br \/>\n      cancer cells by selectively achieving dual ligand blockade (PD-L1 and<br \/>\n      PD-L2) of the PD-1 protein. By blocking PD-1, MK-3475 enables activation<br \/>\n      of the immune system\u2019s T-cells that target cancer, essentially by<br \/>\n      releasing a brake on the immune system.\n    <\/p>\n<p>\n      MK-3475 is being studied in 13 clinical trials estimated to enroll more<br \/>\n      than 4,000 patients across more than 30 types of cancer including:<br \/>\n      bladder, colorectal, gastric, head and neck, melanoma, non-small and<br \/>\n      small cell lung, renal, pancreatic, prostate, triple negative and<br \/>\n      estrogen-receptor positive HER 2-negative breast, gynecologic, and<br \/>\n      hematological malignancies, among others. Additional trials, both as<br \/>\n      monotherapy and in combination with other cancer therapies, are planned.<br \/>\n      For information on Merck\u2019s clinical trials please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2F&amp;esheet=50797474&amp;newsitemid=20140205005453&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2F&amp;index=2&amp;md5=3085633e1d784bf21bda3c2497b83971\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/clinical-trials\/<\/a>.\n    <\/p>\n<p>\n      Breakthrough Therapy designation for MK-3475 in advanced melanoma was<br \/>\n      granted by the U.S. Food and Drug Administration in April 2013. Merck<br \/>\n      announced in January the initiation of a rolling submission of a<br \/>\n      Biologics License Application for MK-3475 in advanced melanoma in the<br \/>\n      U.S. The company expects to complete the submission in the first half of<br \/>\n      2014.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=50797474&amp;newsitemid=20140205005453&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=f44e97c28d479ab0b3e1d0630f344631\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=50797474&amp;newsitemid=20140205005453&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=f6a77f4b096a04ec8ac5195e21dd2b12\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=50797474&amp;newsitemid=20140205005453&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=63412b074ef65dfbbbf1b61f148fb5f5\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=50797474&amp;newsitemid=20140205005453&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=a93d2bad54fc5fd3ffacae09b41292a3\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=50797474&amp;newsitemid=20140205005453&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=70c547ccf6ddf28340896dbd703bf666\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140205005453r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, 908-423-3046<br \/>or<br \/>Claire        Mulhearn, 908-423-7425<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Merck\u2019s investigational anti-PD-1 immunotherapy. The financial terms of the agreements were not disclosed. \u201cMerck clinical scientists intend to explore the potential of our PD-1 inhibitor across a wide range of cancers, both as monotherapy and in combination,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThese new collaborations with Amgen, Incyte and Pfizer underscore our shared determination to evaluate treatment regimens with the potential to provide meaningful benefits to patients suffering from cancer.\u201d Planned investigations include: Pfizer and Merck will evaluate in Phase I\/II clinical studies the safety and efficacy of MK-3475 in combination with Pfizer\u2019s small molecule kinase<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289,56],"class_list":["post-745040","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Merck\u2019s investigational anti-PD-1 immunotherapy. The financial terms of the agreements were not disclosed. \u201cMerck clinical scientists intend to explore the potential of our PD-1 inhibitor across a wide range of cancers, both as monotherapy and in combination,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThese new collaborations with Amgen, Incyte and Pfizer underscore our shared determination to evaluate treatment regimens with the potential to provide meaningful benefits to patients suffering from cancer.\u201d Planned investigations include: Pfizer and Merck will evaluate in Phase I\/II clinical studies the safety and efficacy of MK-3475 in combination with Pfizer\u2019s small molecule kinase\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\\\/\",\"name\":\"Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-02-05T06:40:00+00:00\",\"dateModified\":\"2023-03-22T04:04:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/","og_locale":"en_US","og_type":"article","og_title":"Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Merck\u2019s investigational anti-PD-1 immunotherapy. The financial terms of the agreements were not disclosed. \u201cMerck clinical scientists intend to explore the potential of our PD-1 inhibitor across a wide range of cancers, both as monotherapy and in combination,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThese new collaborations with Amgen, Incyte and Pfizer underscore our shared determination to evaluate treatment regimens with the potential to provide meaningful benefits to patients suffering from cancer.\u201d Planned investigations include: Pfizer and Merck will evaluate in Phase I\/II clinical studies the safety and efficacy of MK-3475 in combination with Pfizer\u2019s small molecule kinase","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:59+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/","name":"Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-02-05T06:40:00+00:00","dateModified":"2023-03-22T04:04:59+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-enters-strategic-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-combination-anti-cancer-regimens-with-mk-3475\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d6f1e090-4b8d-44c8-8345-f6eda50067f1","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Enters-Strategic-Collaborations-with-Amgen-Incyte-and-Pfizer-to-Evaluate-Novel-Combination-Anti-cancer-Regimens-with-MK-3475-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745040\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745040"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}